Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Drug Development
Drug Development · The big question

A Promising New Compound Designed to Disrupt Hepatitis B

Rational design, synthesis, and evaluations of HBV capsid assembly modulators featuring a core of 2-amino-5-(2-amino-2-oxoacetyl)-4-methylthiophene-3-carboxamide.

PubMed1 min readAI-assisted summary
Editorial illustration for Rational design, synthesis, and evaluations of HBV capsid assembly modulators featuring a core of 2-amino-5-(2-amino-2-oxoacetyl)-4-methylthiophene-3-carboxamide.
Editorial illustration

Summary

Hepatitis B remains a massive global health challenge. Current therapies rarely offer a complete cure and often come with difficult side effects. To survive and multiply, the Hepatitis B virus builds a protective shell around its genetic material, known as a capsid. Scientists are increasingly interested in drugs called capsid assembly modulators, or CAMs. These medications work by disrupting this building process, essentially preventing the virus from assembling itself properly.

In a recent study, researchers set out to build a better CAM. They played molecular matchmaker by taking the most effective pieces of two existing antiviral compounds, including one called GLP-26, and fusing them together to create a new series of molecules. After testing the new designs, their standout creation was a lead compound named 14Bc.

When tested in laboratory cell cultures, 14Bc effectively shut down the ability of the Hepatitis B virus to copy its DNA. Beyond its raw antiviral power, 14Bc proved to be highly stable and moved efficiently through biological systems. Strikingly, early evaluations show that this new compound boasts stronger antiviral properties than another similar drug that is already in advanced clinical trials.

Why it matters.

A successful drug targeting the viral capsid could represent a major leap toward a functional cure for chronic Hepatitis B. Because 14Bc demonstrates better metabolic stability and distribution inside the body compared to older baseline compounds, it stands out as a highly optimized candidate for drug development. If it succeeds, it could eventually offer a safer and more effective option for the millions of patients globally who are struggling to manage this chronic infection.

However, it is vital to remember that this research is still in its early preclinical stages. So far, 14Bc has only been evaluated in laboratory cell lines and preliminary distribution models. While the initial results are highly promising, the compound must undergo rigorous clinical trials to confirm that it is both safe and effective in humans before it can become a publicly available treatment.

From the source

The story in numbers.

Lead therapeutic candidate compound
14Bc
In vitro testing cell line
HepG2.2.15
Baseline comparison compound
GLP-26
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Drug Development

A $122M boost for a fast, inside-the-body approach to cell therapy

Create Medicines recently secured $122 million to advance a new class of treatments for cancer and autoimmune diseases. They specialize in CAR-T cell therapy, a treatment that engineers the immune system to fight disease. But instead of the traditional method of removing cells from a patient to alter them in a lab, Create Medicines is developing therapies that work entirely inside the body, a process known as "in vivo" treatment. To achieve this, the therapy uses tiny fat bubbles called lipid nanoparticles to deliver messenger RNA, or mRNA, into the patient. Think of mRNA as a set of biological instructions. Once delivered, these instructions directly teach the patient's existing immune cells, including T cells, natural killer cells, and myeloid cells, to reprogram themselves into disease fighters. The startup has already dosed more than 50 patients, giving it the largest clinical dataset in the in vivo field. They recently began an early-stage clinical trial for an experimental therapy designed to attack solid tumors that carry a specific protein called HER2. Alongside this cancer research, the company is testing other treatments that target proteins called CD19 and BCMA to help patients with autoimmune conditions.

BioPharma Dive1 min read
Drug Development

Supreme Court Protects Access to Common Abortion Pill

The United States Supreme Court has decided to preserve access to mifepristone, a medication used in the most common method of abortion. By rejecting recent restrictions proposed by lower courts, the Supreme Court has ensured that patients can still obtain this widely used drug while an ongoing lawsuit continues to make its way through the legal system. Under this current legal order, patients do not need an in-person visit with a doctor to get the medication. Instead, they are permitted to continue receiving mifepristone directly from pharmacies or through the mail. This ruling maintains the existing distribution methods, meaning that access is expected to remain uninterrupted at least into the following year as further legal proceedings unfold.

STAT News1 min read
Drug Development

Living Implants: Engineered Bacteria Trapped in Gel Fight Infections

What if a medical implant could sense an infection and fight it off automatically? Researchers have created exactly that with a new technology called an "implantable living material." To build it, scientists used a specialized, water-based gel known as a polyvinyl alcohol hydrogel. This material acts as a tiny, flexible fortress. It is uniquely stiff and tough, designed to hold genetically engineered bacteria safely inside for up to six months without them escaping into the surrounding tissue. Inside this protective gel, the researchers trapped a modified version of E. coli bacteria to act as molecular guards. These engineered microbes are programmed to detect chemical signals given off by Pseudomonas aeruginosa, a dangerous pathogen that frequently causes infections around artificial joints. When the trapped bacteria sense the invader, they trigger a targeted self-destruct mechanism. This intentional cellular explosion releases a powerful antibacterial protein that easily passes through the microscopic pores of the gel to kill the infection outside. The research team tested this system in mice with artificial joint infections. Over a three-day treatment period, the living implant significantly reduced the amount of infectious bacteria compared to non-therapeutic controls. By keeping the helpful microbes physically contained while allowing their medicine to flow out, the researchers have found a clever way to turn living cells into localized drug factories.

GEN2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗
A Promising New Compound Designed to Disrupt Hepatitis B — Daily Strand